 <p>TATA MEDICAL CENTER</p>	<p align="center">Tata Medical Center Institutional Review Board</p>	<p>SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026</p>
---	---	--

TMC/ IRB/ SOP-4: Undertaking by the investigator (As per Schedule III, Table 4 of NDCT Rules, 2022)


Annexure 2 (Page 1/3)

Protocol Name: *Assessment of fall risk and it's contributing factors in patients and evaluate the practice adherence to fall prevention SOP among staff nurses at a selected hospital of Kolkata*

Protocol No.:


1. Principal Investigator : Prof. Dr. Piyali Bose, Tata Medical Center, Kolkata, Chief Nursing Superintendent cum Professor
2. Clinical trial conducted at Tata Medical Center, 14, Major Arterial Road (EW) , New Town, Rajarhat, Kolkata – 700 156
3. Ethics Committee: Institutional Review Board, Tata Medical Center, Kolkata
4. Co- Investigator: Dakshina Singh Lohar, M. Sc Nursing student, Tata Medical Center, Kolkata
5. Protocol Title: **Assessment of fall risk and it's contributing factors in patients and evaluate the practice adherence to fall prevention SOP among staff nurses at a selected hospital at Kolkata**
6. Commitments:

Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyl Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution

 TATA MEDICALCENTER	Tata Medical Center Institutional Review Board	SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026
--	---	---

- (i) I have reviewed the clinical protocol and agree that it contains all the necessary information to conduct the study. I will not begin the study until all necessary Ethics Committee and regulatory approvals have been obtained.
- (ii) I agree to conduct the study in accordance with the current protocol. I will not implement any deviation from or changes of the protocol without agreement by the Sponsor and prior review and documented approval/ favourable opinion from the Ethics Committee of the amendment, except where necessary to eliminate an immediate hazard(s) to the trial Subjects or when the change(s) involved are only logistical or administrative in nature.
- (iii) I agree to personally conduct and/or supervise the clinical trial at my site.
- (iv) I agree to inform all Subjects that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent and ethics committee review and approval specified in the GCP guidelines are met.
- (v) I agree to report to the Sponsor all adverse experiences that occur in the course of the study in accordance with the regulatory and GCP guidelines.


Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyil Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution

 TATA MEDICAL CENTER	Tata Medical Center Institutional Review Board	SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026
---	---	---

Annexure 2 (Page 2/3)

- (vi) I have read and understood the information in the Investigator's brochure, including the potential risks and side effects of the drug.
- (vii) I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are suitably qualified and experienced and they have been informed about their obligations in meeting their commitments in the trial.
- (viii) I agree to maintain adequate and accurate records and to make those records available for audit/inspection by the Sponsor, Ethics Committee, Licensing Authority or their authorized representatives, in accordance with regulatory and GCP provisions. I will fully cooperate with any study related audit conducted by regulatory officials or authorized representatives of the Sponsor.
- (ix) I agree to promptly report to the IRB/EC all changes in the clinical trial activities and all unanticipated problems involving risks to human Subjects or others.
- (x) I agree to inform all serious adverse events to the Sponsor as well as the IRB/EC within 24hrs of their occurrence.
- (xi) I will maintain confidentiality of the identification of all participating study patients and assure security and confidentiality of study data.
- (xii) I have/do not have any conflicts of Interest (COI) in the study i.e. Financial/Personal or others.
- (xiii) I agree to comply with all other requirements, guidelines and statutory obligations as applicable to clinical Investigators participating in clinical trials

Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyil Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution

 TATA MEDICAL CENTER	<p style="text-align: center;">Tata Medical Center Institutional Review Board</p>	<p>SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026</p>
---	--	--


8 . Signature of the Investigator with Date

Name of the Investigator: DAKSHINA SINGH LOHAR.

Signature of the Investigator: Dakhina Singh Lohar.

Date: 04.04.26 ,

Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyil Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution

 TATA MEDICAL CENTER	Tata Medical Center Institutional Review Board	SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026
---	---	---

Annexure 2 (Page 3/3)

I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are suitably qualified and experienced and they have been informed about their obligations in meeting their commitments in the trial.

I agree to maintain adequate and accurate records and to make those records available for audit/inspection by the Sponsor, Ethics Committee, Licensing Authority or their authorized representatives, in accordance with regulatory and GCP provisions. I will fully cooperate with any study related audit conducted by regulatory officials or authorized representatives of the Sponsor.


I agree to promptly report to the Ethics Committee all changes in the clinical trial activities and all unanticipated problems involving risks to human Subjects or others.

I agree to inform all unexpected serious adverse events to the Sponsor, Licensing Authority as well as the Ethics Committee and copy to the Head of the Institution within one day of their occurrence.

I will maintain confidentiality of the identification of all participating study patients and assure security and confidentiality of study data.

I agree to comply with all other requirements, guidelines and statutory obligations as applicable to clinical Investigators participating in clinical trials

Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyil Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution

 TATA MEDICAL CENTER	Tata Medical Center Institutional Review Board	SOP : TMC/IRB/SOP-13 Version No.: 13.1 Effective Date : 03-10-25 To be reviewed (on or before): 31-03-2026
---	---	---

I agree to declare conflict of interest, if any during the discussion and decision taking in the EC Meetings.

Name of the Principal Investigator: Prof. Dr. Piyali Bose

Signature of the Principal Investigator:

Piyali Bose

Date: 4.4.26

Prof (Dr) Piyali Bose
PhD in Nursing, M. Sc Pediatric Nursing
Chief Nursing Superintendent
Tata Medical Center, Kolkata

Prepared by : Dr Tanuj Chawla/ Dr Indranil Mallick	Reviewed by: Prof Siddhartha Roy	Approved by: Dr Pattatheyil Arun
IRB Secretariat	TMC-IRB Chairperson	Head of the Institution